Nihar Desai: Allo-HSCT Outcomes in MDS/MPN Overlap Syndromes
Sergio Rodríguez, Allogeneic Bone Marrow Transplant Fellow at Princess Margaret Cancer Centre, posted on X:
“New Study Alert.
Our team retrospectively analyzed our cohort on allogeneic HSCT outcomes in patients with MDS/MPN overlap syndromes—a rare and challenging group of hematologic neoplasms.
Study population: 75 patients with
•CMML (64%)
•MDS/MPN-NOS (31%)
•MDS/MPN with neutrophilia (11%), who underwent allo-HSCT between 2010–2023. Median age: 61.
Outcomes at 2 years:
•OS: 51.6%
•Relapse: 17.4%
•NRM (1y): 28.1%
•GRFS: 24.8%
•GIII–IV aGvHD at D+100: 13%
PTCy-based GvHD prophylaxis (often w/ ATG) was associated with:
- Better OS (HR 0.5, p = 0.03)
- Lower NRM (HR 0.4, p = 0.03)
- Improved GRFS (HR 0.5, p = 0.009) …and no increase in relapse risk.
High-risk mutations (ASXL1, RUNX1, EZH2, etc.) were associated with relapse trends. GvHD (16%) and infection (17%) remain key causes of NRM.
Bottom line:
- Allo-HSCT offers curative potential in MDS/MPN overlap neoplasms.
- PTCy (± ATG) appears to improve survival outcomes without added relapse risk.
- Further multicenter studies needed.”
Nihar Desai, Bone Marrow Transplant Physician at Princess Margaret Cancer Center, posted on X:
“Excellent thread summarising key findings of our latest publication fromPrincess Margaret Cancer Centre.”
Title: Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms
Authors: Nihar Desai, Sergio Rodriguez-Rodriguez, Carol Chen, Tommy Alfaro Moya, Eshrak Al-Shaibani, Igor Novitzky-Basso, Ivan Pasic, Fotios V. Michelis, Auro Viswabandya, Dennis Kim (Dong Hwan), Rajat Kumar, Jonas Mattsson, Arjun Datt Law
Read The Full Article at Wiley.
More posts featuring Nihar Desai.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023